Inscripta® Announces Biomanufacturing of a Rapidly Growing Anti-aging Skincare Ingredient
Inscripta Achieves Important Milestone and Demonstrates Its Novel Whole Genome Engineering Biotechnology Platform With Accelerated Timelines
Read More
BEDOUKIAN RESEARCH INC. PARTNERS WITH INSCRIPTA TO SUSTAINABLY DEVELOP AND MANUFACTURE NATURALLY PRODUCED INGREDIENTS
July 19th, 2023: Pleasanton, CA and Danbury, CT: Bedoukian Research Inc. (BRI), a leading global supplier of flavor & fragrance...
Read More
INSCRIPTA® ACQUIRES INFINOME BIOSCIENCES AND SESTINA BIO TO ADVANCE SUSTAINABLE BIOMANUFACTURING
With the addition of Infinome and Sestina Bio, Inscripta adds to its portfolio of cutting-edge technologies for biomanufacturing products for...
Read More
KALSEC® PARTNERS WITH INFINOME™ BIOSCIENCES TO SUSTAINABLY DEVELOP AND MANUFACTURE PRECISION FERMENTATION PRODUCTS
Through advanced technology and processes, Infinome is creating sustainable manufacturing solutions for Kalsec.
Read More
Aldevron Licenses the Manufacturing of MAD7, a Type-V CRISPR Nuclease From Inscripta
A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease
Read More
Inscripta® Appoints Kristala Prather, PhD to its Board of Directors
Inscripta adds a distinguished MIT Professor and synthetic biology pioneer, Dr. Kristala Prather, to the Board of Directors.
Read More
Hunterian Medicine® Licenses Inscripta’s MAD7™ Nuclease to Advance Gene Editing Research and Development
Inscripta and Hunterian pioneer new program to provide access to novel CRISPR enzymes for biotherapeutic development
Read More
Inscripta® Announces the First Commercial Shipment of Its Onyx® Digital Genome Engineering Platform and Closes $150 Million in New Financing
GeneMill at the University of Liverpool receives first benchtop Onyx platform in Europe Financing round led by Fidelity and T....
Read More
Inscripta® Launches the World’s First Benchtop Platform for Digital Genome Engineering
The Onyx® platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a...
Read More
In the First Year of Release, Inscripta®’s MAD7™ CRISPR Enzyme is Widely Adopted by the Gene-Editing Community
Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research
Read More
- 1
- 2